Short Interest in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Decreases By 20.4%

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) saw a large decline in short interest during the month of February. As of February 27th, there was short interest totaling 549,755 shares, a decline of 20.4% from the February 12th total of 690,455 shares. Based on an average daily volume of 324,103 shares, the days-to-cover ratio is currently 1.7 days. Currently, 0.6% of the shares of the stock are sold short. Currently, 0.6% of the shares of the stock are sold short. Based on an average daily volume of 324,103 shares, the days-to-cover ratio is currently 1.7 days.

Hedge Funds Weigh In On Inventiva

Several institutional investors and hedge funds have recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC grew its stake in shares of Inventiva by 55.6% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock valued at $142,000 after buying an additional 9,212 shares during the period. Creative Planning purchased a new stake in shares of Inventiva during the 2nd quarter valued at approximately $32,000. Commonwealth Equity Services LLC lifted its holdings in Inventiva by 19.6% in the fourth quarter. Commonwealth Equity Services LLC now owns 77,561 shares of the company’s stock valued at $361,000 after acquiring an additional 12,704 shares during the last quarter. Virtu Financial LLC acquired a new position in Inventiva in the fourth quarter valued at approximately $60,000. Finally, XTX Topco Ltd purchased a new position in Inventiva in the fourth quarter worth approximately $84,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a research report on Thursday, January 22nd. HC Wainwright set a $24.00 price objective on shares of Inventiva and gave the company a “buy” rating in a research note on Wednesday, January 28th. Leerink Partners assumed coverage on shares of Inventiva in a report on Monday, January 12th. They issued an “outperform” rating and a $12.00 price objective for the company. Barclays initiated coverage on shares of Inventiva in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $18.00 target price on the stock. Finally, Guggenheim lowered their target price on Inventiva from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $17.00.

Inventiva Trading Down 2.9%

Shares of IVA stock traded down $0.18 on Friday, hitting $5.99. 141,750 shares of the stock traded hands, compared to its average volume of 328,033. Inventiva has a twelve month low of $2.70 and a twelve month high of $7.98. The firm’s 50-day moving average price is $6.18 and its two-hundred day moving average price is $5.36.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.